Diabetic Macular Edema Clinical Trial
Official title:
To Understand the Barriers and Facilitators of Diabetic Retinopathy Screening & Follow-up: An Exploratory Study From India and Thailand
Verified date | September 2020 |
Source | Lions Club International Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Brief Summary: Diabetic retinopathy (DR) is a leading cause of visual impairment and has
major public health implications globally and especially in countries such as India where the
prevalence of diabetes is high. With timely screening and intervention, the disease
progression to blindness can be prevented but several barriers exist to the provision of
care. The long term aim is to identify the barriers to DR screening and to plan potential
interventional strategies. From the qualitative study, the reasons such as lack of awareness
or knowledge, distance to travel, lack of reminder system were identified as a reason for
poor follow-up. This lead to the development of interventional strategies.
This was a randomized, investigator-masked clinical trial that was conducted in a tertiary
eye care centre in South India. Consecutive patients with diabetes who were residents in
Chennai and its vicinity of approximately 100 km radius and who were undergoing repeated
intravitreal injections for DME were recruited into the trial. The aim of the study is to
investigate the effect of SMS informational reminders among patients with Diabetic macular
edema for the follow-up. They study consists of 2 groups, SMS reminder group receives the
reminders 1 week and 2 days prior to the scheduled appointments with the concerned doctor on
a particular date and time, whereas other group does not receive any reminders for the
appointment schedule. After the follow-up, the patients will be screened for the attendance
at the review visit.
Status | Completed |
Enrollment | 200 |
Est. completion date | August 14, 2019 |
Est. primary completion date | August 14, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Adults with > 40 years of age - Diagnosed as centre involving Diabetic macular edema (DME) - Patients who received intravitreal injections for DME - Ability to give informed consent Exclusion Criteria: - Patients from outside the area of residence who stayed more than 100 km from the hospital - Patients with ocular co-morbidities other than DME |
Country | Name | City | State |
---|---|---|---|
India | Rajiv Raman | Chennai | Tamilnadu |
Lead Sponsor | Collaborator |
---|---|
Lions Club International Foundation |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Attendance rates in patients with diabetic macular edema receiving short messaging services | To investigate the effect of SMS informational reminders on adherence with scheduled eye examinations among patients with center involving DME receiving intravitreal injections in a tertiary eye care institute in South India. | 7 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03953807 -
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated
|
Phase 4 | |
Completed |
NCT03622580 -
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
|
Phase 3 | |
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Terminated |
NCT04603937 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Terminated |
NCT04611152 -
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
|
Phase 3 | |
Active, not recruiting |
NCT04108156 -
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
|
Phase 3 | |
Completed |
NCT02867735 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
|
Phase 1 | |
Withdrawn |
NCT03629210 -
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
|
Phase 2 | |
Withdrawn |
NCT02842541 -
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
|
Phase 1 | |
Completed |
NCT02221453 -
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
|
Phase 2 | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Completed |
NCT02979665 -
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
|
||
Completed |
NCT02000102 -
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
|
N/A | |
Completed |
NCT02088229 -
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
|
N/A | |
Terminated |
NCT00779142 -
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
|
N/A | |
Completed |
NCT01171976 -
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00989989 -
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
|
Phase 3 | |
Completed |
NCT01259609 -
Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
|
N/A | |
Completed |
NCT00683176 -
Effect of Choline Fenofibrate (SLV348) on Macular Edema
|
Phase 2 | |
Terminated |
NCT00768040 -
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
|
Phase 2 |